Articles

In the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study, first-line ibrutinib + venetoclax treatment resulted in high rates of undetectable MRD in both peripheral blood and bone marrow of patients with chronic lymphocytic leukemia (CLL). Read More ›

Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses. Read More ›

For patients with chronic lymphocytic leukemia who are treated with acalabrutinib, disease progression is largely attributed to specific mutations in Bruton tyrosine kinase (BTK). Acalabrutinib resistance mechanisms are similar to those seen with ibrutinib. Read More ›

Exciting research from the annual ASH conference showed that a new drug combination led to significant improvements in patients with systemic amyloid light chain amyloidosis. This could mean more treatment options for patients with a very limited choice of therapies. Read More ›

In a study that compared VenR (venetoclax plus rituximab) with standard chemoimmunotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), initial reports showed superior progression-free survival for VenR, as well as long-term benefits after patients stopped therapy. Read More ›

Use of a time-limited triplet combination of acalabrutinib, venetoclax, and obinutuzumab in patients with chronic lymphocytic leukemia offers high rates of undetectable minimal residual disease in bone marrow with acceptable tolerability. Read More ›

When given daratumumab along with standard-of-care treatment, patients with newly diagnosed, transplant-ineligible multiple myeloma lived longer than those who received standard of care alone. Read More ›

Results of the ECOG 1912 trial comparing chemoimmunotherapy with the oral BTK inhibitor ibrutinib plus rituximab in younger people with chronic lymphocytic leukemia (CLL). Read More ›

Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions. Read More ›

CAR T-cell therapy, a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells, has led to exciting results in other types of cancer…could it soon be used to treat multiple myeloma? Read More ›